table s4 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors

table s4 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors

<p>suppl. table 4</p>

Saved in:

書目詳細資料
主要作者:	Elena Llano (14963220) (author)
其他作者:	Anne Laure Todeschini (14963223) (author), Natalia Felipe-Medina (14963226) (author), María D. Corte-Torres (14963229) (author), Yazmine B. Condezo (14963232) (author), Manuel Sanchez-Martin (14963235) (author), Sara López-Tamargo (14963238) (author), Aurora Astudillo (14963241) (author), Xose S. Puente (14935902) (author), Alberto M. Pendas (14963244) (author), Reiner A. Veitia (14963247) (author)
出版:	2025
主題:	Cancer Cancer Biology Molecular and Cellular Biology Carcinogenesis Animal models of carcinogenesis Genome Biology Comparative transcriptomics Gynecological Cancers Ovarian cancer
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Table S2 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
由: Elena Llano (14963220)
出版: (2025)

Table S3 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
由: Elena Llano (14963220)
出版: (2025)

Table S5 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
由: Elena Llano (14963220)
出版: (2025)

table s1 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
由: Elena Llano (14963220)
出版: (2025)

Supplemental Table S3 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis
由: Yeh Wang (14964041)
出版: (2025)

Supplemental Table S4 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis
由: Yeh Wang (14964041)
出版: (2025)

Table S1 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
由: Aditi S. Khatpe (15293176)
出版: (2025)

Table S10 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
由: Aditi S. Khatpe (15293176)
出版: (2025)

Table S11 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
由: Aditi S. Khatpe (15293176)
出版: (2025)

Table S12 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
由: Aditi S. Khatpe (15293176)
出版: (2025)

Table S13 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
由: Aditi S. Khatpe (15293176)
出版: (2025)

Table S14 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
由: Aditi S. Khatpe (15293176)
出版: (2025)

Table S15 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
由: Aditi S. Khatpe (15293176)
出版: (2025)

Table S2 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
由: Aditi S. Khatpe (15293176)
出版: (2025)

Table S3 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
由: Aditi S. Khatpe (15293176)
出版: (2025)

Table S4 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
由: Aditi S. Khatpe (15293176)
出版: (2025)

Table S9 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
由: Aditi S. Khatpe (15293176)
出版: (2025)

Data Sheet 1_MRI-based radiomic clustering identifies a glioblastoma subtype enriched for neural stemness and proliferative programs.csv
由: Zhongyi Zhang (219440)
出版: (2025)

Data Sheet 2_MRI-based radiomic clustering identifies a glioblastoma subtype enriched for neural stemness and proliferative programs.pdf
由: Zhongyi Zhang (219440)
出版: (2025)

Supplementary Figures S1-S4 from The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
由: Karolin Heinze (16540724)
出版: (2025)

Supplementary Tables S1-S5 from The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
由: Karolin Heinze (16540724)
出版: (2025)

Image 5_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
由: Naohiro Wakisaka (407153)
出版: (2025)

Table 1_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.xlsx
由: Naohiro Wakisaka (407153)
出版: (2025)

Image 4_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
由: Naohiro Wakisaka (407153)
出版: (2025)

Image 2_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
由: Naohiro Wakisaka (407153)
出版: (2025)

Image 3_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
由: Naohiro Wakisaka (407153)
出版: (2025)

Image 1_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
由: Naohiro Wakisaka (407153)
出版: (2025)

44d_RNAseq_data from A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes
由: Anna Wuestefeld (14963115)
出版: (2025)

Supplementary Table S1 from Estrogen-DNA Adducts and Breast Cancer Risk in Premenopausal Asian Women
由: Ching-Hung Lin (15110557)
出版: (2025)

Supplementary Table 1 from Spatial Transcriptomics Depict Ligand–Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors
由: Sammy Ferri-Borgogno (15307295)
出版: (2025)

Supplementary Table 2 from Spatial Transcriptomics Depict Ligand–Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors
由: Sammy Ferri-Borgogno (15307295)
出版: (2025)

Supplementary Table 3 from Spatial Transcriptomics Depict Ligand–Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors
由: Sammy Ferri-Borgogno (15307295)
出版: (2025)

Supplementary Table 4 from Spatial Transcriptomics Depict Ligand–Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors
由: Sammy Ferri-Borgogno (15307295)
出版: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
由: Martina S.J. McDermott (15206951)
出版: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
由: Martina S.J. McDermott (15206951)
出版: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
由: Martina S.J. McDermott (15206951)
出版: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
由: Martina S.J. McDermott (15206951)
出版: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
由: Martina S.J. McDermott (15206951)
出版: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
由: Martina S.J. McDermott (15206951)
出版: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
由: Martina S.J. McDermott (15206951)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_2nf5hurf4f6skin3so84l82a9e